Literature DB >> 22234743

Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient.

Yoshinobu Ichiki1, Takeshi Hanagiri, Mitsuhiro Takenoyama, Tetsuro Baba, Yoshika Nagata, Makiko Mizukami, Tetsuya So, Masakazu Sugaya, Manabu Yasuda, Hidetaka Uramoro, Kosei Yasumoto.   

Abstract

PURPOSE: MHC antigens and adhesion molecules, such as the intracellular adhesion molecule (ICAM-I), play an important role in cellular immune response. We examined the expression patterns of these molecules in both primary and metastatic esophageal carcinoma cells from the same patient and evaluated the cellular immune responses against these cells.
MATERIALS AND METHODS: In the esophageal cancer patient (H122), tumor cell lines were established from primary and subcutaneous metastatic lesions. We compared the expression of cell surface molecules on the metastatic tumor cell line (H122SC) with that on the primary tumor cell line (H122ESO) using flow cytometry. Moreover, we analyzed the differences in cellular immune responses against these cell lines, which expressed similar levels of the Tara antigen, using the Tara antigen-specific CTL clone.
RESULTS: H122SC ICAM-1 expression was significantly lower in H122ESO, and the Tara antigen-specific CTL clone produced lower levels of TNF in response to H122SC than H122ESO. ICAM-1 transfection into the H122SC rendered these cells as sensitive to the CTL clone as the H122ESO.
CONCLUSION: The metastatic tumor cells displayed lower regulated ICAM-1 expression levels and were less sensitive to specific CTLs. ICAM-1 downregulation may be one mechanism by which tumor cells escape immunologic surveillance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234743     DOI: 10.1007/s00595-011-0083-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  35 in total

1.  Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.

Authors:  R Chiari; F Foury; E De Plaen; J F Baurain; J Thonnard; P G Coulie
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

2.  Refluxtions on esophageal cancer: can we swallow the changes?

Authors:  J Tepper
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study.

Authors:  L R Coia; B D Minsky; B A Berkey; M J John; D Haller; J Landry; T M Pisansky; C G Willett; J P Hoffman; J B Owen; G E Hanks
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

4.  Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis.

Authors:  G J Zhang; I Adachi
Journal:  Int J Oncol       Date:  1999-01       Impact factor: 5.650

5.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity.

Authors:  J C Becker; R Dummer; A A Hartmann; G Burg; R E Schmidt
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

6.  Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer.

Authors:  Y Ueda; H Yamagishi; Y Tanioka; H Fujiwara; N Fuji; T Itoh; H Fujiki; T Yoshimura; T Oka
Journal:  Hepatogastroenterology       Date:  1999-05

7.  Serum cell adhesion molecules in patients with colorectal cancer.

Authors:  T Kitagawa; K Matsumoto; K Iriyama
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses.

Authors:  S Rhiannon Jenkinson; Neil A Williams; David J Morgan
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

9.  ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway.

Authors:  Ahmed Hamaï; Franck Meslin; Houssem Benlalam; Abdelali Jalil; Maryam Mehrpour; Florence Faure; Yann Lecluse; Philipe Vielh; Marie-Françoise Avril; Caroline Robert; Salem Chouaib
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 10.  Esophageal cancer.

Authors:  L R Coia; E R Sauter
Journal:  Curr Probl Cancer       Date:  1994 Jul-Aug       Impact factor: 3.187

View more
  4 in total

1.  Association between the genetic variations within TBX21 gene promoter and the clinicopathological characteristics of esophageal squamous cell carcinoma in a high-risk Chinese population.

Authors:  Huihui Li; Hongchao Zhen; Lei Han; Bo Yan; Jing Yu; Shengtao Zhu; Bangwei Cao
Journal:  Tumour Biol       Date:  2015-01-11

2.  PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.

Authors:  Matteo Fassan; Francesco Cavallin; Vincenza Guzzardo; Andromachi Kotsafti; Melania Scarpa; Matteo Cagol; Vanna Chiarion-Sileni; Luca Maria Saadeh; Rita Alfieri; Ignazio Castagliuolo; Massimo Rugge; Carlo Castoro; Marco Scarpa
Journal:  Cancer Med       Date:  2019-08-20       Impact factor: 4.452

3.  Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.

Authors:  Xuan Wang; Fang-Cheng Zhang; Hong-Yang Zhao; Xiao-Ling Lu; Yun Sun; Zhi-Yong Xiong; Xiao-Bing Jiang
Journal:  Tumour Biol       Date:  2014-05-10

4.  Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.

Authors:  Andromachi Kotsafti; Melania Scarpa; Francesco Cavallin; Matteo Fassan; Roberta Salmaso; Andrea Porzionato; Luca Saadeh; Matteo Cagol; Rita Alfieri; Carlo Castoro; Massimo Rugge; Ignazio Castagliuolo; Marco Scarpa
Journal:  Oncoimmunology       Date:  2020-08-12       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.